Stock Events

Stock Events

Evaxion A/S 

$3.29
34
+$0.17+5.54% 14:10 Today

Statistics

Day High
3.31
Day Low
3.12
52W High
12.15
52W Low
2.71
Volume
28,621
Avg. Volume
199,616
Mkt Cap
27.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29MayExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.6
-1.07
-0.53
0
Expected EPS
-0.55
Actual EPS
-1.6

Financials

-102.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.53MRevenue
-7.71MNet Income

Analyst Ratings

16.00Average Price Target
The highest estimate is 16.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVAX. It's not an investment recommendation.
Apple
5
AAPL
Microsoft
5
MSFT
Amazon
5
AMZN
AMD
5
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap58.11B
Moderna is a leader in mRNA technology, directly competing with Evaxion's focus on developing vaccines and treatments using similar technology.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech competes in the mRNA vaccine space, similar to Evaxion's approach to vaccine development, making them direct competitors.
Novavax
NVAX
Mkt Cap1.69B
Novavax is involved in the development of vaccines for infectious diseases, competing with Evaxion's infectious disease vaccine programs.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is focused on gene editing, a technology that can be seen as complementary or competitive to Evaxion's AI-driven approach to drug development.
Intellia Therapeutics
NTLA
Mkt Cap1.79B
Intellia Therapeutics is another company working on CRISPR technology, potentially competing with Evaxion's efforts in genetic-based therapies.
Editas Medicine
EDIT
Mkt Cap496.06M
Editas Medicine operates in the gene editing space, which could compete with Evaxion's technology in developing treatments for various diseases.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a large pharmaceutical company with a broad portfolio that includes vaccines and treatments that could compete with Evaxion's products.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines and therapeutics that could compete with Evaxion's pipeline.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, and influenza, competing with Evaxion's infectious disease focus.
Merck
MRK
Mkt Cap370.89B
Merck is a global healthcare company that develops vaccines and therapeutics, including for infectious diseases, competing with Evaxion's product pipeline.

About

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Show more...
CEO
Helen Katrina Tayton-Martin
Employees
46
Country
Denmark
ISIN
US29970R3030

Listings

XNAS
US
EVAX
BOATS
BOATS
EVAX.BOATS

0 Comments

Share your thoughts

FAQ

What is Evaxion A/S stock price today?▼
The current price of EVAX is $3.29 USD — it has increased by +5.54% in the past 24 hours. Watch Evaxion A/S stock price performance more closely on the chart.
What is Evaxion A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Evaxion A/S stocks are traded under the ticker EVAX.
Is Evaxion A/S stock price growing?▼
EVAX stock has risen by +10.74% compared to the previous week, the month change is a +6.45% rise, over the last year Evaxion A/S has showed a +11.86% increase.
What is Evaxion A/S market cap?▼
Today Evaxion A/S has the market capitalization of 27.46M
What were Evaxion A/S earnings last quarter?▼
EVAX earnings for the last quarter are -1.6 USD per share, whereas the estimation was -0.55 USD resulting in a -190.91% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Evaxion A/S revenue for the last year?▼
Evaxion A/S revenue for the last year amounts to 7.53M USD.
What is Evaxion A/S net income for the last year?▼
EVAX net income for the last year is -7.71M USD.
How many employees does Evaxion A/S have?▼
As of September 08, 2026, the company has 46 employees.
In which sector is Evaxion A/S located?▼
Evaxion A/S operates in the Health & Wellness sector.
When did Evaxion A/S complete a stock split?▼
The last stock split for Evaxion A/S was on January 14, 2025 with a ratio of 1:5.
Where is Evaxion A/S headquartered?▼
Evaxion A/S is headquartered in Horsholm, Denmark.